Key facts
- This page summarizes Jonathan David Schwartz's Form 4 filing for ROCKET PHARMACEUTICALS, INC. (RCKT).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 13 Feb 2025, 16:01.
Jonathan David Schwartz - 11 Feb 2025 Form 4 Insider Report for ROCKET PHARMACEUTICALS, INC. (RCKT)
- Reporting relationship
- Chief Medical & Gene Therapy Officer
- Issuer ticker
- RCKT
- Reported as of
- 11 Feb 2025
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 13 Feb 2025, 16:01:34 UTC
- Prior SEC filing
- 27 Feb 2025
- Next SEC filing
- 20 May 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Martin Wilson, as attorney-in-fact for Jonathan Schwartz
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Jonathan David Schwartz filed Form 4 for ROCKET PHARMACEUTICALS, INC. (RCKT) on 13 Feb 2025.
Change
- Previous filing in this sequence was filed on 27 Feb 2025.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
RCKT
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +80,318
- Change %
- +47%
- Price
- $0.000000
- Shares after
- 252,731
- Date
- 11 Feb 2025
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
RCKT
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +119,682
- Change %
- Price
- $0.000000
- Shares after
- 119,682
- Date
- 11 Feb 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 119,682
- Exercise price
- $9.88
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Represent RSUs that convert to common stock on a one-for-one basis. One-third (1/3) of such RSUs will become fully vested on February 11, 2026, with the remaining shares vesting in equal quarterly installments over the following two years.
Footnote F2
This option represents a right to purchase a total of 119,682 shares of the Issuer's Common Stock, one-third of which will become fully vested and exercisable on February 11, 2026, with the remaining shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer.
SEC remarks
Chief Medical & Gene Therapy Officer